Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joseph Desimone
Denovotherapies, Llc, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cleveland Clinic Lerner College of Medicine of CWRU
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project involves the use of technology developed by Dr. Saunthararajah that was licensed by University of Illinois, Chicago to EpiDestiny, LLC. DeNovo is a wholly owned subsidiary of EpiDestiny.
Dr. Saunthararajah is the IND Holder/Sponsor on the technology being evaluated in this award.
i. Public disclosure of the financial interest in presentations and publications, to personnel who participate in the research project, to the IRB/IACUC, to government committees, and in any press releases related to the technology. ii. The Innovation Management & Conflict of Interest Office may designate individuals to review research related to the companies or the companies' competitors, including trial design, data analysis and reporting and manuscript publication and submission. For the human subjects portion of this project, Dr. Saunthararajah may not participate in the consenting, enrollment, day-to-day management or clinical end-point (including primary end-point) evaluation in this study. However, if there are unexpected adverse events, he may provide guidance to the investigators if requested. He may not have access to the tracking database for this study. An independent statistician, who has no financial interest in the Companies and who does not report to Dr. Saunthararajah will be responsible for all the data analysis. iii. The inventors will not accept royalties for the use of the technology at Cleveland Clinic.
A Novel, Non-Cytotoxic, Epigenetic Therapeutic for Sickle Cell Disease
NARRATIVE Sickle cell disease (SCD) continues to exact a terrible toll of morbidity and mortality in the USA and worldwide, underscoring the need for scientifically rational, cost-effective oral therapy for disease modification. We have already generated clinical proof of principle of a novel non-cytotoxic epigenetic therapy approach (oral tetrahydrouridine-decitabine, THU-Dec) that has the potential to meet this need, however, there are fundamental technical barriers related to the synthesis and formulation of the new chemical entity THU that need to be overcome if commercialization and clinical adoption are to be feasible. In this Fast-Track project, we have assembled the team of experts that can overcome these hurdles through hypothesis-driven process optimization and formulation development, culminating with a Phase IIa clinical trial, thereby positioning this novel non-cytotoxic epigenetic therapeutic for rapid movement through pivotal clinical trials, to NDA, and to patients in need.
Filed on October 11, 2017.
Tell us what you know about Joseph Desimone's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Joseph Desimone”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | $100,000 - $149,999 |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | $80,000 - $99,999 |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | Value cannot be readily determined |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | $0 - $4,999 |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | Value cannot be readily determined |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | Value cannot be readily determined |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | $0 - $4,999 |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | $100,000 - $149,999 |
| Joseph Desimone | Univ of North Carolina Chapel Hill | Conflict of Interest | Liquidia Technologies | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.